Migraine-advanced preventative treatments: the British Association for the Study of Headache Clinical Practice Recommendations and Consensus Guidance.

This document offers practical recommendations on advanced migraine treatments. It was developed by the British Association for the Study of Headache. The guidance is based on literature, expert opinions, and real-world experiences. It targets all healthcare professionals involved in headache management. New treatments, like calcitonin gene-related peptide-targeted therapies and botulinum toxin, expand options. However, treatment accessibility varies across the UK. A multidisciplinary group created this clinical guidance, including consultants, nurses, and general practitioners. Key clinical questions were agreed upon by consensus from the group. Recommendations relied on selective evidence searches, including systematic reviews and meta-analyses. Some recommendations needed amendments to reach the required consensus level of 75%. The guidance addresses common dilemmas faced in advanced migraine treatments. It aims to enhance patient access and experiences with these treatments. This document will be updated as new evidence becomes available in the future. Clinical relevance: This guidance provides essential recommendations to improve access and care for migraine patients using advanced treatment options.